Ludmila Prudkin

Ludmila Prudkin

UNVERIFIED PROFILE

Are you Ludmila Prudkin?   Register this Author

Register author
Ludmila Prudkin

Ludmila Prudkin

Publications by authors named "Ludmila Prudkin"

Are you Ludmila Prudkin?   Register this Author

30Publications

1002Reads

13Profile Views

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

J Clin Oncol 2015 Apr 5;33(12):1334-9. Epub 2015 Jan 5.

Ian J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087318PMC
April 2015

Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.

Cell Oncol (Dordr) 2015 Feb 4;38(1):39-48. Epub 2014 Sep 4.

Molecular Oncology Laboratory, Vall d'Hebron Institute of Oncology, Passeig Vall d'Hebron, 119-129, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-014-0192-6DOI Listing
February 2015

A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.

Clin Cancer Res 2014 May 14;20(10):2793-804. Epub 2014 Mar 14.

Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1837DOI Listing
May 2014

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Clin Cancer Res 2013 Dec 18;19(24):6976-86. Epub 2013 Oct 18.

Authors' Affiliations: Oncology Biomarker Development, Portfolio Management and Operations, Translational Oncology, Biostatistics, and Exploratory Clinical Development, Genentech Inc., DNA Way, South San Francisco, California; Experimental Therapeutics, Molecular Pathology, Breast Cancer and Melanoma, Gastrointestinal and Endocrine Tumors Groups, and Medical Oncology Service, Vall d'Hebron Institute of Oncology, Barcelona; Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; and Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0978DOI Listing
December 2013

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Cancer Discov 2013 Nov 15;3(11):1238-44. Epub 2013 Aug 15.

1Vall d'Hebron Institut d'Oncologia; 2Vall d'Hebron Institut de Recerca; 3Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona; 4Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain; and 5Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0132DOI Listing
November 2013

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Mol Cancer Ther 2012 Sep 21;11(9):2062-71. Epub 2012 Jun 21.

Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/content/11/9/2062.full.pdf
Web Search
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-12
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-12-0290DOI Listing
September 2012

EphA2 in the early pathogenesis and progression of non-small cell lung cancer.

Cancer Prev Res (Phila) 2009 Dec 24;2(12):1039-49. Epub 2009 Nov 24.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-09-0212DOI Listing
December 2009

Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development.

Cancer Res 2009 Sep 8;69(18):7439-48. Epub 2009 Sep 8.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-08-3792DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745504PMC
September 2009

miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1.

Mol Cancer Res 2009 Aug 11;7(8):1234-43. Epub 2009 Aug 11.

Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390-8591, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-08-0507DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741087PMC
August 2009

Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.

Clin Cancer Res 2009 Jul 16;15(13):4423-30. Epub 2009 Jun 16.

Departments of Thoracic/Head and Neck Medical Oncology, Biostatistics, and Pathology, The University of Texas M. D. Anderson Cancer Center, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-09-0473DOI Listing
July 2009

A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer.

Cancer Res 2007 Jun;67(12):5889-95

Division of Translational Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-0245DOI Listing
June 2007

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.

Ann Diagn Pathol 2006 Oct;10(5):306-15

Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2006.06.011DOI Listing
October 2006

[Incomplete Carney's Triad and arterial hypertension in a young woman].

Medicina (B Aires) 2006 ;66(1):43-5

Unidad A de Clínica Medica, Servicio de Cirugía General, Sección Endocrinología, Servicio de Gastroenterología, Servicio de Patología, Hospital Juan A. Fernández, Buenos Aires.

View Article

Download full-text PDF

Source
August 2006